Jamjoom Pharmaceuticals Factory First Quarter 2025 Earnings: EPS: ر.س2.24 (vs ر.س1.47 in 1Q 2024)

Simply Wall St · 05/08 03:05

Jamjoom Pharmaceuticals Factory (TADAWUL:4015) First Quarter 2025 Results

Key Financial Results

  • Revenue: ر.س457.5m (up 19% from 1Q 2024).
  • Net income: ر.س157.0m (up 53% from 1Q 2024).
  • Profit margin: 34% (up from 27% in 1Q 2024). The increase in margin was driven by higher revenue.
  • EPS: ر.س2.24 (up from ر.س1.47 in 1Q 2024).
earnings-and-revenue-growth
SASE:4015 Earnings and Revenue Growth May 8th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Jamjoom Pharmaceuticals Factory Earnings Insights

Looking ahead, revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Pharmaceuticals industry in Asia.

Performance of the market in Saudi Arabia.

The company's shares are down 2.0% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We have a graphic representation of Jamjoom Pharmaceuticals Factory's balance sheet and an in-depth analysis of the company's financial position.